The 43 most recent market catalysts affecting $CVS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Bearish
Impact 75
CVS Health Shares Decline Amid Reports of Potential Medicare Advantage Reimbursement Changes
CVS Health, along with other major health insurers like Humana and Centene, experienced a notable share price decline due to reports indicating potential tightening of US governmen…
Nov 16, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Lowers Price Target on CVS Health
RBC Capital Markets lowered its price target on CVS Health (CVS) from $113 to $108. This action, despite maintaining an 'Outperform' rating, signals a recalibration of the firm's v…
Nov 16, 2026
Corporate Catalyst
Neutral
Impact 60
CVS Health Releases Research on GLP-1 Benefits and Affordability
CVS Health published a study using Aetna claims data on GLP-1 medications, finding that while they improve patient outcomes and reduce medical spending, these savings do not fully …
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 65
Deutsche Bank Adjusts Price Target and Rating on CVS Health
Deutsche Bank has adjusted its outlook on CVS Health, reducing its price target and downgrading the stock to a neutral rating. This move reflects a reassessment of CVS's market pos…
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 65
CVS Caremark Reports $1.5 Billion in Gross Savings Through Biosimilar Adoption Strategy
CVS Caremark, the PBM arm of CVS Health, reported $1.5 billion in gross savings from its biosimilar adoption strategy. This is a significant win for CVS, demonstrating the effectiv…
Nov 10, 2026
Corporate Catalyst
Bearish
Impact 55
Argus Research Adjusts CVS Health Price Target
Argus Research, a financial analysis firm, has adjusted its price target for CVS Health, reducing it from $114 to $105. This change reflects a re-evaluation of CVS Health's stock b…
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 75
CVS Health Provides Strategic Update at 8th Annual Wolfe Research Healthcare Conference
CVS Health disclosed a material reduction in the expected dis-synergies related to its planned separation into two distinct businesses, from over $1 billion to approximately $500 m…
Nov 6, 2026
Corporate Catalyst
Neutral
Impact 55
CVS Health EVP and Group President Prem S. Shah Purchases $2 Million in Company Stock
Prem S. Shah, an EVP and Group President at CVS Health, purchased over $2 million worth of company stock, increasing his direct ownership significantly. This insider buying signals…
Nov 6, 2026
Corporate Catalyst
Neutral
Impact 55
CVS Health Appoints New Board Member
CVS Health Corporation announced the appointment of a new board member, the Chief Data & Analytics Officer from J.P. Morgan, effective November 2026. This addition reflects CVS's o…
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 85
CVS Health Announces Plan to Separate into Two Independent Companies
CVS Health announced a significant strategic decision to split its operations into two independent, publicly traded companies by 2028. This separation will create one entity focuse…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 92
CVS Health Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
CVS Health announced robust third-quarter 2026 financial results, reporting $108.4 billion in revenue, a 5.4% year-over-year increase, and a significant return to net income of $2.…
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 85
CVS Health Explores Potential Separation of Retail Pharmacy Business
CVS Health is exploring a spin-off of its retail pharmacy business, which accounts for approximately one-third of its revenue. This move would unwind the vertical integration strat…
Nov 2, 2026
Corporate Catalyst
Bearish
Impact 65
Mark Cuban Alleges Public Companies Found Overcharging by Major Insurers
Mark Cuban, speaking on a podcast, revealed that several public companies discovered significant overcharging by major insurers (CVS Health, UnitedHealth Group, Cigna) after using …
Oct 31, 2026
Corporate Catalyst
Neutral
Impact 75
Department of Labor Finalizes PBM Transparency Regulation
The Department of Labor has finalized a new regulation mandating PBMs disclose 'spread pricing' and rebates, effective July 2027. This move aims to increase transparency and lower …
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 55
CVS Health Announces 'Beyond Housing' Strategy for Health and Well-Being
CVS Health has announced its 'Beyond Housing' strategy, a corporate initiative to integrate housing support into its health and well-being framework. This move signifies a strategi…
Oct 28, 2026
Corporate Catalyst
Bearish
Impact 65
CVS Health to Terminate SilverScript Choice PDP in 13 Regions for 2027
CVS Health is discontinuing its SilverScript Choice PDP in 13 regions, impacting nearly a million Medicare Part D beneficiaries. This decision is a strategic portfolio adjustment b…
Oct 28, 2026
Corporate Catalyst
Bearish
Impact 55
CVS Health Reports Worsening Shortages of Estradiol Injections
CVS Health's 8-K filing reveals a worsening shortage of specific estradiol injection strengths, a critical component of hormone replacement therapy. This issue is significant becau…
Oct 28, 2026
Corporate Catalyst
Neutral
Impact 75
US Department of Labor to Require PBM Transparency Disclosures
The US Department of Labor's impending regulations will force PBMs like CVS Health's Caremark and Cigna's Express Scripts to disclose detailed financial information, including drug…
Oct 27, 2026
Corporate Catalyst
Bullish
Impact 65
CVS Health Engages in Medicare Negotiations to Expand Pharmacist Roles and GLP-1 Access
CVS Health is engaging in significant negotiations with Medicare to expand the scope of pharmacist services, particularly in chronic disease management, and to address access to hi…
Oct 21, 2026
Corporate Catalyst
Bearish
Impact 65
CVS Health and Other Major Insurers Scale Back Medicare Advantage Footprints
CVS Health, via Aetna, is reducing its Medicare Advantage offerings for 2026, part of a wider industry trend seeing a 10% year-over-year decrease in non-special-needs MA plans. Thi…
Oct 13, 2026
Corporate Catalyst
Bearish
Impact 65
CVS Agrees To Pay $315M For Illegally Filling Unlawful Opioid Prescriptions And For Submitting False Claims To The Federal Government
CVS Health has reached a $315 million settlement with the Department of Justice regarding allegations of illegally filling opioid prescriptions and submitting false claims. This pa…
Oct 13, 2026
Corporate Catalyst
Neutral
Impact 65
'CVS agrees to pay $315 million to settle Justice Department case over opioid prescriptions' - Associated Press
CVS Health has agreed to a $315 million settlement with the Justice Department over allegations of improperly dispensing opioid prescriptions. This payment resolves a long-standing…
Oct 12, 2026
Corporate Catalyst
Bearish
Impact 55
Leerink Partners Maintains Outperform on CVS Health, Lowers Price Target to $112
Leerink Partners analyst Michael Cherny maintained an 'Outperform' rating on CVS Health, signaling continued confidence in the company's long-term prospects. However, the reduction…
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 65
CVS Health's Aetna Says Strong Medicare Star Ratings Boost Confidence in Return to Appropriate Margins
CVS Health's Aetna division has achieved strong Medicare Advantage Star Ratings for 2027, with a significant majority of its members enrolled in highly-rated plans. This is crucial…
Oct 8, 2026
Corporate Catalyst
Bearish
Impact 85
CVS Health shares are trading lower after the CMS 2027 Medicare Advantage Part D Release gave the company's Silverscript Insurance contract, a large Medicare PDP contract, a 2.5-star rating. A lower rating could turn people toward competing plans, which can hurt downstream prescription volume at its retail business.
The 2.5-star rating for CVS's Silverscript Medicare Part D plan is a significant negative catalyst. Medicare Advantage plans with lower ratings often experience reduced enrollment …
Sep 21, 2026
Market Technicals
Bearish
Impact 55
Top 3 Health Care Stocks That May Rocket Higher In September
Benzinga Pro has identified CVS Health Corp, Steris PLC, and Baxter International Inc as oversold in the healthcare sector, with RSI values below 30. This technical indicator sugge…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 55
CVS Health's Aetna Reduces Administrative Tasks For Cancer Care
CVS Health's Aetna is expanding its bundled prior authorization program for all cancer types, initially for Medicaid members and eventually across all business lines by 2027. This …
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 55
CVS Health Unit Aetna Announces Expansion Of Prior Authorization Bundles Across All Cancer Types For Members In Eligible Medicaid States As Of September 1, With Plans To Expand Across All Lines Of Business In 2027
CVS Health's Aetna unit is expanding its bundled prior authorization program for cancer treatments, initially for Medicaid members in specific states, with a full rollout across al…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 55
Guardian Pharmacy Services Announces Acquisition Of Assets From Nautilus Pharmacy, Including Prescription Files And Inventory; Terms Not Disclosed
This acquisition is a corporate catalyst, indicating consolidation within the specialized pharmacy sector, specifically long-term care. While the financial terms are not disclosed,…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 55
Argus Research Maintains Buy on CVS Health, Raises Price Target to $114
Argus Research, through analyst Steve Silver, has maintained its 'Buy' rating on CVS Health and raised its price target from $104 to $114. This action signals a continued bullish s…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 85
CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal
CVS Health delivered a robust second-quarter performance, surpassing Wall Street's estimates and prompting an upward revision of its fiscal 2026 adjusted earnings guidance. This fi…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
CVS Health shares are trading lower despite reporting better-than-expected Q2 financial results and raising its FY26 adjusted EPS guidance above estimates. The stock may be experiencing some profit taking after rising almost 60% from the end of Q1.
This headline indicates a classic 'sell the news' or profit-taking scenario. Even though CVS Health delivered strong financial results and raised future guidance, the stock's subst…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
CVS shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 EPS guidance. Also, the company issued FY26 revenue guidance above estimates.
This headline represents a significant positive corporate catalyst for CVS. Better-than-expected earnings and, more importantly, raised long-term guidance (FY26 EPS and revenue) si…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
CVS stock has given up its prior gain. CVS shares were trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 EPS guidance. Also, the company issued FY26 revenue guidance above estimates.
This headline indicates a significant corporate catalyst for CVS, as strong Q2 results and raised FY26 guidance are typically very positive. The 'giving up' of gains, however, sugg…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
CVS Health Exec Says Co. Will See Membership Declines In Care Mark Next Year
CVS Health's executive team, during a conference call, indicated an expected decline in membership for its Caremark pharmacy benefit management (PBM) segment next year. This is a s…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
CVS Health Raises FY2026 Adj EPS Guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 Est; FY2026 Revenue expected to be more than $414.000M vs $409.235B Est
CVS Health announced a substantial increase in its fiscal year 2026 adjusted EPS guidance from $7.30-$7.50 to $7.90-$8.10, significantly exceeding the analyst estimate of $7.45. Co…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
CORRECTION: CVS Health Raises FY2026 Adj EPS Guidance from $7.30-$7.50 to $7.90-$8.10 vs $7.45 Est; FY2026 Revenue expected to be more than $414.000B vs $409.235B Est
This headline is a significant corporate catalyst for CVS Health. The upward revision of both EPS and revenue guidance for FY2026, particularly the substantial increase in EPS, ind…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 65
CVS Health Retools Its Weight Management Program To Make It Easier For Eligible Adults To Access Clinical Care, Navigate Medication Costs And Get Ongoing Support For GLP-1 Therapy
CVS Health is strategically retooling its weight management program to capitalize on the booming GLP-1 market. By offering all FDA-approved GLP-1s, collaborating with Eli Lilly for…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 75
FTC Says CVS Caremark Settlement Could Save Consumers Upto $13 Billion
CVS Health's Caremark subsidiary has reached a settlement with the FTC, resolving a significant antitrust case that alleged rebate-driven practices artificially inflated drug price…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 65
CVS Health's CVS Caremark Announces Settlement With U.S. Federal Trade Commission To Resolve All Outstanding Litigation, Probe
CVS Health's CVS Caremark has reached a global settlement with the FTC, addressing all pending litigation and investigations. This is significant because it removes a cloud of regu…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on CVS Health, Raises Price Target to $123
Wells Fargo analyst Stephen Baxter maintained an 'Overweight' rating on CVS Health and raised the price target from $103 to $123. This upgrade signals increased confidence from a m…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 65
Federal Health Watchdog Projects $5.56 Billion in Recoveries and Savings, Despite Enforcement Hitting Two-Year Low
The HHS OIG's report highlights a significant projected recovery of $5.56 billion, primarily from enforcement actions against healthcare providers and insurers. While overall enfor…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.